As previously reported, Piper Sandler initiated coverage of Janux Therapeutics (JANX) with an Overweight rating and $42 price target While noting that investor sentiment has waned over the course of 2025 following the announcement of completion of the JANX007 dose escalation and emergence of competitor clinical data, it continues to think JANX007 is “a differentiated, potentially best-in-class program” in metastatic castration-resistant prostate cancer. The firm views the recent stock pullback offering “an attractive entry point” ahead of clinical updates due later this year, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Janux Therapeutics initiated with an Overweight at Piper Sandler
- Buy Rating for Janux Therapeutics Driven by Promising Tumor-Conditional Masking Platform and Strategic Collaborations
- Promising Future for Janux Therapeutics: Buy Rating Backed by Strong Clinical Profile and Strategic Trials
- Promising Developments and Strategic Expansion at Janux Therapeutics: Analyst Sets $70 Price Target
- Buy Rating for Janux Therapeutics Driven by Promising Pipeline and Strong Financial Position